CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenue:
Total revenue	$ 2,569	$ 2,135
Operating expenses:
Cost of goods sold		620
Research and development	319	21,964
General and administrative	4,636	6,816
Restructuring	0	2,401
Total operating expenses	4,955	31,801
Operating loss	(2,386)	(29,666)
Other income, net	347	952
Non-cash interest expense on liability related to sales of future royalties and milestones	(2,867)	(1,982)
Net loss	$ (4,906)	$ (30,696)
Net loss per share:
Basic (in dollars per share)	$ (3.22)	$ (20.24)
Diluted (in dollars per share)	$ (3.22)	$ (20.24)
Weighted average shares:
Basic (in shares)	1,524,116	1,516,336
Diluted (in shares)	1,524,116	1,516,336
Other comprehensive income, net of tax of $0:
Change in unrealized gains on available-for-sale marketable securities		$ 69
Total comprehensive loss	$ (4,906)	(30,627)
Collaborative revenue
Revenue:
Total revenue	1,198	788
Commercial supply revenue
Revenue:
Total revenue		640
Clinical compound revenue
Revenue:
Total revenue	48	84
Other revenue
Revenue:
Total revenue	$ 1,323	$ 623